_(1).jpg)
Tevogen.AI, the artificial intelligence arm of Tevogen Bio Holdings Inc., has deepened its partnership with Microsoft and Databricks to develop the beta version of its PredicTcell model, focusing on oncology. This strategic collaboration aims to enhance cancer immunotherapy development through advanced AI-driven solutions.
Tevogen.AI collaborates with Microsoft and Databricks for PredicTcell beta.
Beta version targets oncology, building on virology dataset.
Enhances accuracy of immunologically active peptide predictions.
Aims to accelerate cancer immunotherapy development.
Includes advanced analytics and visualization tools for R&D.
Explores external market opportunities for revenue growth.
Tevogen.AI’s expanded collaboration with Microsoft and Databricks leverages the Databricks Data Intelligence Platform to curate a comprehensive oncology dataset. This dataset, combined with the existing virology dataset, enhances the accuracy of the PredicTcell model’s alpha version. The beta version focuses on predicting immunologically active peptides, a critical component in developing targeted cancer therapies.
The PredicTcell beta model is designed to streamline the development of cancer immunotherapies by improving the precision of peptide predictions. “We have been extremely fortunate to work with such great organizations like Microsoft and Databricks to build the alpha version of our foundational AI model,” said Mittul Mehta, Chief Information Officer and Head of Tevogen.AI. “Oncology represents one of the most impactful areas for AI in drug discovery, given the complexity of the disease and the limited availability of high-quality datasets.” This advancement could significantly reduce development timelines for cancer treatments.
Tevogen.AI is developing advanced analytics and visualization tools to support its internal R&D teams. These tools will enable researchers to better interpret complex datasets, driving innovation in immunotherapy. The collaboration also positions Tevogen.AI to explore external market opportunities, potentially creating new revenue streams through its AI-driven solutions.
The partnership between Tevogen.AI, Microsoft, and Databricks marks a pivotal step in advancing AI-powered oncology solutions. By enhancing the PredicTcell model and integrating cutting-edge analytics, Tevogen.AI is poised to lead in the development of next-generation cancer immunotherapies, delivering impactful solutions for the healthcare industry.
TechIntelPro empowers B2B technology decision-makers with the latest industry trends, deep insights, leadership perspectives and actionable intelligence to drive both organizational and professional milestones—and thrive on the tech pulse.